Cravath Steers J&J Buy Of Skadden-Led Ambrx In $2B Deal
Pharmaceutical industry giant Johnson & Johnson, advised by Cravath Swaine & Moore LLP, is buying San Diego, California-based clinical-stage biopharmaceutical company Ambrx Biopharma Inc., advised by Skadden Arps Slate Meagher &...To view the full article, register now.
Already a subscriber? Click here to view full article